INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN)

被引：0
|
作者：
Barratt, Jonathan [1 ]
Leifke, Eckhard [2 ]
Whitaker, Steve [2 ]
DeTulleo, Louis [2 ]
Lafayette, Richard [3 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Omeros Corp, Seattle, WA USA
[3] Stanford Univ, Stanford, CA 94305 USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP201
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    [J]. HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [32] Treatment of Severe Hematopoietic Stem Cell transplant-associated Thrombotic Microangiopathy (HCT-TMA) with the masp-2 Inhibitor Narsoplimab (OMS721)
    Romera, Irene
    Martinez Munoz, Maria
    de Miguel, Carlos
    Salcedo, Isabel
    Manso, Marta
    Alarcon, Ana
    Naya, Daniel
    Perez de Camino, Begona
    Bautista, Guiomar
    Cabrera, Rafael
    Duarte, Rafael F.
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 578 - 578
  • [33] Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis
    Lafayette, Richard
    Maes, Bart
    Israni, Rubeen
    Lin, Celia
    Wei, Xuelian
    Barbour, Sean
    Phoon, Richard
    Kim, Sung Gyun
    Tesar, Vladimir
    Floege, Juergen
    Jha, Vivekanand
    Barratt, Jonathan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I53 - I55
  • [34] Interim Results from an Ongoing Global Phase 1 Study of Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency
    Lopez Lorenzo, J. L.
    Shah, A. J.
    Sevilla, J.
    Navarro, S.
    Llanos, L.
    de Camino Gaisse, B. Perez
    Sanchez, S.
    Zubicaray, J.
    Glader, B.
    Chien, M.
    Bustamante, O.
    Zeini, M.
    Choi, G.
    Nicoletti, E.
    Rao, G. R.
    Roncarolo, M. G.
    Bueren, J. A.
    Schwartz, J. D.
    Segovia, J. C.
    [J]. HUMAN GENE THERAPY, 2022, 33 (23-24) : A58 - A58
  • [35] Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the Masp-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
    Pullman, William
    Brough, Mary
    Soto, Carolina
    Meng, Tze-Chiang
    [J]. BLOOD, 2022, 140 : 8493 - 8494
  • [36] Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy: interim results from the phase 2 NURTURE study
    Ryan, M.
    De Vivo, D.
    Bertini, E.
    Hwu, W.
    Crawford, T.
    Swoboda, K.
    Finkel, R.
    Kirschner, J.
    Kuntz, N.
    Parsons, J.
    Butterfield, R.
    Topaloglu, H.
    Ben Omran, T.
    Sansone, V.
    Jong, Y.
    Shu, F.
    Foster, R.
    Bhan, I.
    Fradette, S.
    Farwell, W.
    [J]. NEUROMUSCULAR DISORDERS, 2019, 29 : S185 - S185
  • [37] Nusinersen in Infants who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy: Interim Results from the Phase 2 NURTURE Study
    Butterfield, R.
    De Vivo, D.
    Bertini, E.
    Hwu, W-L
    Crawford, T.
    Swoboda, K.
    Finkel, R.
    Kirschner, J.
    Kuntz, N.
    Parsons, J.
    Ryan, M.
    Topaloglu, H.
    Ben Omran, T.
    Sansone, V
    Jong, Y-J
    Shu, F.
    Johnson, K.
    Foster, R.
    Bhan, I
    Fradette, S.
    Farwell, W.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S117 - S117
  • [38] Interim Results from the NEXUS Open-Label Phase 2 Study on the Safety and Efficacy of Leriglitazone in the Treatment of Childhood Cerebral Adrenoleukodystrophy
    Musolino, P. L.
    Mallack, E.
    Garcia-Cazorla, A.
    Ribeiro, J.
    Sevin, C.
    Yazbeck, E.
    Rosewich, H.
    Jimenez, S.
    Chia-Yi, Chiang G.
    Rapalino, O.
    Caruso, P.
    Helmer, K.
    Balentine, D.
    Pascual, S.
    [J]. ANNALS OF NEUROLOGY, 2023, 94 : S33 - S34
  • [39] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
  • [40] INTERIM RESULTS OF A PHASE 2 STUDY OF XMAB®5871, A REVERSIBLE B CELL INHIBITOR, IN IGG4-RELATED DISEASE
    Stone, J. H.
    Wallace, Z. S.
    Perugino, C. A.
    Fernandes, A. D.
    Patel, P. S.
    Foster, P. A.
    Zack, D. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 711 - 712
12345